The retinal pigment epithelium (RPE) comprises a monolayer of cells located between the neuroretina and the choriocapillaries. The RPE serves several important functions in the eye: formation of the blood-retinal barrier, protection of the retina from oxidative stress, nutrient delivery and waste disposal, ionic homeostasis, phagocytosis of photoreceptor outer segments, synthesis and release of growth factors, reisomerization of alltrans-retinal during the visual cycle, and establishment of ocular immune privilege. Age-related macular degeneration (AMD) is the leading cause of blindness in developed countries. Dysfunction of the RPE has been associated with the pathogenesis of AMD in relation to increased oxidative stress, mitochondrial destabilization and complement dysregulation. Photobiomodulation or near infrared light therapy which refers to non-invasive irradiation of tissue with light in the far-red to near-infrared light spectrum (630-1000 nm), is an intervention that specifically targets key mechanisms of RPE dysfunction that are implicated in AMD pathogenesis. The current evidence for the efficacy of photobiomodulation in AMD is poor but its safety profile and proposed mechanisms of action motivate further research as a novel therapy for AMD.
INTRODUCTION
The retinal pigment epithelium (RPE) comprises a monolayer of cells located between the retinal photoreceptors and the fenestrated choriocapillaris, which is basally bordered by the elastin and collagen-rich Bruch's membrane (BM). It serves several important functions in maintaining photoreceptor health. Its tight junctions protect the neuroretina from blood-borne toxins and its light-absorbing pigments mitigate photo-oxidative stress. The RPE delivers nutrients and disposes waste products including phagocytosis of photoreceptor outer segments (POS). It is fundamental to the visual cycle by recycling of retinoids. Furthermore, the RPE contributes to the production and secretion of growth factors and provides ocular immune privilege.
Age-related macular degeneration (AMD) accounts for 8.7% of worldwide blindness and is the leading cause of blindness in developed countries. 1 Although the pathogenesis of AMD remains incompletely understood, there is evidence that dysfunction of the RPE resulting from oxidative stress, impairment of nutrient delivery as well as energy metabolism and complement dysregulation, contributes to the pathogenesis of AMD.
Photobiomodulation, also known as near infrared (NIR) light therapy, is known to increase cellular metabolism, energy supply and metabolic repair processes. 2, 3 Hence, photobiomodulation of dysfunctional RPE could conceivably restore function and attenuate the pathogenesis of AMD.
The aim of this review is to summarize the structure and functions of the RPE and its role in the pathogenesis of age-related macular degeneration, and to discuss the current evidence and potential of photobiomodulation in AMD.
STRUCTURE
The RPE comprises a polygonal monolayer of cells, the size and shape of which vary as a function of retinal eccentricity, from a diameter of 14 μm at the fovea to considerably larger (60 μm) in the peripheral retina. [4] [5] [6] [7] [8] [9] The height of RPE cells is a 10-15 μm at the fovea and approximately 7.5 μm at the periphery. 10 The cell density of the RPE is greater in the fovea compared to the equator. 11 With age, peripheral RPE density declines, but this is preserved at the fovea due to inward migration of peripheral RPE. 12 Approximately 30-40 photoreceptors overlie each RPE cell. 11 The RPE projects microvilli apically that enshroud the POS. Long thin apical microvilli measuring 5-7 μm in length are projected from the RPE and enshroud the POS, facilitating transepithelial and retina-to-RPE transport. Similarly, the basal surface of the RPE contains complex infoldings to support molecular movement. This apical-basal polarity is also reflected in the organization of RPE organelles and membrane proteins. Melanosomes are situated apically whilst the nucleus, mitochondria, endoplasmic reticulum, lysosomes, Golgi apparatus, lipofuscin and melanolipofuscin granules are located towards the basal side. 7, 13 The polar distribution of different combinations of ion channels and pumps on either the apical or basal membrane enables the diffusion of certain ions in specific directions in order to transport nutrients to photoreceptors and remove retinal waste products as well as the maintenance of subretinal ionic homeostasis as elucidated below.
BLOOD-RETINAL BARRIER
Tight junctions between adjacent RPE cells are attached to the actin cytoskeleton and form part of the outer blood-retinal barrier.
14 This prevents paracellular transport of large molecules, toxins, bloodborne products and water. 15 As a result of the tight junctional barrier produced by the RPE, resistance to paracellular movement is 10 times higher than resistance to transcellular movement. 16, 17 However, this resistance is plastic, as permeability of the tight junctions can change in the presence of diffusible factors produced from the neural retina. 18 One such factor is vascular endothelial growth factor (VEGF) which has been implicated in the breakdown of the outer blood-retinal barrier in diabetic macular oedema. 19, 20 Hypoxia and hyperglycaemia may upregulate hypoxia inducible factor 1 alpha and therefore VEGF expression, resulting in altered tight junction proteins. [20] [21] [22] During the development of the RPE, tight junctions tend to be leaky, but these become progressively less permeable due to secretion of these diffusible factors from the neural retina.
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PROTECTION FROM OXIDATIVE DAMAGE
The RPE is responsible for the absorption of reflected and scattered light. This helps to both optimize image quality and protect the retina from oxidative damage caused by reactive free radicals, which result from the combination of constant RPE exposure to light, the high RPE metabolic activity, the elevated local oxygen tension and the photooxidation of lipofuscin. 6, 7 The pigment melanin, which is stored and synthesized in melanosomes, absorbs and filters harmful light, particularly in the blue wavelength region of the spectrum which is known to cause photo-oxidation of lipofuscin, a lipid-protein pigment that accumulates with age and from phagocytosis of the POS. 24, 25 Melanin has been identified as having additional antioxidative properties, including counteracting singlet oxygen and scavenging reactive oxygen species (ROS). 26, 27 Melanin density increases towards the centre of the retina, reaching its peak at the fovea, contributing to the clinically darker appearance of the fovea and surrounding macula. Melanin within the RPE decreases uniformly after the age of 40. 7 Another mechanism of defence against oxidative damage is the intrinsic antioxidant defence system of the RPE, which comprises both enzymes, such as catalase and superoxide dismutase, and non-enzymatic antioxidants such as α-tocopherol, β-carotene and ascorbate. [28] [29] [30] [31] [32] Glutathione has been implicated as another antioxidant in the RPE with functions including perioxidase-reduction of lipid hydroperoxides, maintenance of ascorbate in its reduced form as well as detoxification of reactive products of lipid peroxidation such as 4-hydroxynonenol. 33, 34 
TRANSPORT OF NUTRIENTS, WASTES AND WATER
The close anatomical apposition of the RPE to the photoreceptors is necessary for facilitating the transcellular movement of nutrients, wastes, fluid and ions.
The delivery of nutrients, including glucose, ascorbate and fatty acids, from the choroidal vasculature to the photoreceptors occurs through transporters within the RPE membranes. Glucose is passively transported through numerous GLUT1 (glucose transporter 1) and GLUT3 (glucose transporter 3) transporters on both the apical and basal membranes. 35, 36 More recently, additional glucose transporters GLUT2 (glucose transporter 2) and GLUT5 (glucose transporter 5) have been identified on the apical and basolateral membranes in cultured human RPE cells. 37 Ascorbate is a carbohydrate vitamin that is vital in hydroxylation reactions and biosynthetic pathways, especially in the production of collagen and glycosaminoglycans which are components of the interphotoreceptor matrix (IPM) and BM. [38] [39] [40] It is also an effective antioxidant and scavenger of superoxide radicals. The transcellular movement of ascorbic acid across the RPE occurs through active sodium-dependent transport that is reduced by presence of ouabain, 2,4-dinitrophenol and dehydroascorbic acid. 40 Photoreceptor membranes, which comprise a significant portion of the omega 3 fatty acid docosahexanoic acid (DHA), are continuously renewed and added to the POS as photoreceptor tips are shed and phagocytized by the RPE. 41 Thus, photoreceptors require a constant supply of DHA. Initially, DHA is produced in the liver from the dietary precursor α-linelonic acid before being carried by lipoproteins in the circulation to the RPE. Transport through RPE membranes occurs through a concentrationdependent manner. [41] [42] [43] DHA acid has also been identified as a precursor to neuroprotectin 1, which protects RPE from oxidative damage and may also play a role in RPE retinoid transport by modulating binding between interphotoreceptor binding protein (IRPB) and 11-cis-retinal. 44 Lactic acid, a metabolic end product produced in excess by the retina and thought to be specifically released from POS and to a lesser extent, photoreceptor inner segments has been proposed to act as a nutrient for RPE. 45, 46 Analysis of bovine eyes revealed the distribution of lactate on the retinal surface was seven times greater than at the RPE whilst glucose was 50 times greater at the RPE than the retinal surface. The distribution of these fuels suggests RPE consumes more lactate and releases more glucose from the retina. 46 However no comparison has been made in vivo and the mechanism of lactate metabolism in RPE remains unclear. From the subretinal space, lactic acid enters the RPE apical membrane by active transport through lactate-H+ co-transporter monocarboxylate transporter 1 (MCT1) and the Na + -dependent co-transporter. Irrespective of whether lactate acts as a fuel source for RPE cells or not, excess levels of this compound are removed through the RPE basolateral membrane via monocarboxylate transporter 3 (MCT3) and the Na + -lactate exchanger. 47, 48 Constant transport of water away from the subretinal space to the choriocapillaris is required to maintain close apposition of the RPE and photoreceptors.
Large volumes of subretinal fluid are generated from metabolic turnover in photoreceptors as well as intraocular fluid flux from the vitreous body towards the retina. Water travels across the RPE to the choriocapillaris by active transport through the aquaporin 1 channel, identified in studies of cultured rat and human RPE. 49, 50 Water transport is also facilitated by the transport of ions such as Cl − and K + which will be elaborated below.
TRANSEPITHELIAL TRANSPORT AND MAINTENANCE OF SUBRETINAL ION LEVELS
The RPE plays a major role in preserving excitability of photoreceptors by careful regulation of subretinal ionic concentration through transepithelial transport of ions (Fig. 1) . The apical Na + /K + ATPase pump, which results in outflow of Na + and influx of K + , provides the energy gradient that is vital to transepithelial transport. [51] [52] [53] The Na + /K + ATPase, together with the polarized distribution of other channels and transporters, produce a high subretinal sodium concentration and high potassium concentration in the RPE cytosol. The elevated subretinal sodium is critical to the dark current which is produced by the entry of sodium ions through cGMP (cyclic guanosine monophosphate) gated channels, resulting in depolarization of photoreceptors. Apical entry of sodium occurs through the Na
− cotransporter and exit occurs basolaterally through mechanisms that are unclear. 54 However, most intracellular sodium ions are recycled through the apical Na + /K + ATPase to maintain the high subretinal sodium concentration.
The RPE also effectively compensates for ionic changes such as fluctuation in potassium levels during phototransduction. Potassium can enter the RPE apically through Na + /K + ATPase or Na +2 -K + -2Cl cotransporter and leave basolaterally or apically through K + channels. 54 Whilst in the dark, the potassium concentration is 5 mM with net transepithelial efflux of potassium from the subretinal space to the choroid. Exposure to light causes the hyperpolarization of photoreceptors leading to the closure of cGMP gated Na + channels in the outer segment membranes and reduced K + efflux from the inner segment. Subsequently, the subretinal potassium concentration decreases to 2 mM which triggers hyperpolarization of the RPE apical membrane and activation of inward rectifying K + channels on the apical membrane, causing K + flow into the subretinal space. In the early phase of RPE hyperpolarization, the apical Na
− co-transporter reverses direction, further increasing K + movement to the subretinal space, resulting in the restoration of subretinal potassium concentration. 55 Chloride, a vital facilitator for fluid movement, enters through the RPE apical membrane via the Na
− co-transporter before exiting basolaterally via voltagedependent chloride and CIC-2 channels. The basolateral Cl − /HCO 3− exchanger, an important channel in pH regulation, transports chloride back into the RPE. An additional efflux channel for chloride in RPE cells is the CFTR channel on the basolateral aspect. 54 CFTR channels along with the CIC family channels have been found to be highly susceptible to oxidative stress in human foetal and adult RPE cultures. 56, 57 Chloride channel dysfunction and altered fluid transport secondary to oxidative stress may play a role in AMD. 58 Chloride transport, similar to potassium transport in the RPE is regulated by calcium, cAMP (cyclic adenosine monophosphate), epinephrine and ATP (adenosine triphosphate). 57, 59 Transepithelial transport of HCO 3− is intrinsically associated with pH regulation of the subretinal space and the RPE cell itself. At high pH, HCO 3− travels apically into the RPE via the Na + /HCO 3− transporter and leaves basolaterally in exchange with Cl− through the HCO 3− /Cl − exchanger. Conversely, at low pH HCO 3− enters basolaterally through the HCO 3-/Cl − exchanger before travelling to the subretinal space through the Na + /HCO 3− transporter. 60 
PHAGOCYTOSIS OF POS
Photoreceptor membranes undergo a renewal process whereby the outer segment tips are shed and subsequently phagocytosed by RPE before new outer segments are constructed at the cilum. This is Figure 1 . Glucose enters and exits through GLUT transporters 1,2,3 and 5. Lactate enters apically through MCT1 and lactate Na + co-transporter before exiting basolaterally via MCT3 and Na + lactate exchanger. The apical Na + /K + ATPase pump, which results in outflow of Na + in exchange for K + , provides the energy gradient that for transepithelial transport. Sodium enters apically through Na
− co-transporter and exits basolaterally through mechanisms that are unclear. Potassium can enter apically through Na + /K + ATPase or Na +2 -K + -2Cl co-transporter and leave basolaterally or apically through K + channels. Chloride enters the RPE apically via the Na
− co-transporter and exits basolaterally via voltage-dependent chloride and CIC-2 channels. The basolateral Cl − /HCO 3− exchanger, which is involved in pH regulation, facilitates chloride entry into the RPE cell. CFTR channels on the basolateral aspect facilitates the exit of chloride. Transport of water occurs through aquaporin channels distributed apically and basolaterally.
necessary for several reasons: to maintain photoreceptor excitability, to recycle nutrients, including DHA and retinal and to prevent oxidative damage from photo-oxidation of damaged POS lipid and protein components.
The process of POS phagocytosis is triggered by interactions with ligand receptors including CD36(Cluster of Differentiation 36), 61, 62 the mannose-6-phosphate receptor, 63 alpha V beta5 integrin, 64 MerTK (C-MER proto-oncogene Tyrosine Kinase), 65, 66 CD81 (cluster of differentiation 81) 67 and L-type calcium channels. 68 Initially, specific binding of the POS to the RPE apical membrane leads to induction of a secondary messenger cascade. This results in the ingestion of the POS before undergoing lysosomal digestion. The components from lysosomal digestion are either recycled back to photoreceptors as nutrients or transported into the choroid vasculature as waste.
PRODUCTION AND SECRETION OF GROWTH FACTORS
In order to preserve the neural retina and choroid architecture, the RPE produces and secretes several protein mediators, cytokines and growth factors, including platelet-derived growth factor (PDGF), pigment epithelium-derived growth factor (PEDF), vascular endothelial growth factor, fibroblast growth factors (FGF), transforming growth factor β (TGF β), insulin-like growth-I (IGF-I), ciliary neurotrophic factor (CNTF), tissue inhibitor of metalloprotease (TIMP), lens epithelium-derived growth factor (LEDGF) and members of the interleukin family. [69] [70] [71] [72] [73] [74] [75] Photoreceptors are protected by the neuroprotectant growth factors PEDF, FGF, CNTF, LEDGF and IGF-I whilst PDGF modulates cell growth and healing. PEDF, which is secreted from the RPE apical membrane, has anti-angiogenic properties and helps maintain the fenestrations of the choriocapillaris endothelium. TGF β moderates inflammation and regulates extracellular matrix synthesis and turnover, a function shared by TIMP. VEGF, which is secreted from basal RPE, basically has an opposite role to PEDF and promotes angiogenesis and regulates the permeability of the choriocapillaris. VEGF overexpression has been implicated as a key player in the pathogenesis of choroidal neovascularisation (CNV) in AMD. 76, 77 The expression of VEGF is regulated by numerous factors, including mechanical stress, hypoxia advanced glycation end products (AGE), cytokines (interleukin 1 and TNF), vasopressor hormones (angiotensin II), vasopressin, growth factors (TGFβ, FGF and PDGF) and L-type Ca 2+ channels. 78 
REISOMERIZATION OF ALL-TRANS-RETINAL AND TRANSPORT OF RETINOIDS IN THE VISUAL CYCLE
The visual cycle is the fundamental process by which a photon is converted into an electrical signal in the retina. The triggering event of the visual cycle is the absorption of light by rhodopsin in the POS which results in one of its components, the chromophore 11-cis-retinal, to be converted to all-trans-retinal. This results in a conformational change in opsin, a G-protein coupled receptor component of rhodopsin, which activates the regulatory protein transducin to initiate signal transduction cascades leading to closure of cyclic GMP-gated cation channels, hyperpolarization of the photoreceptor cell membrane and, ultimately, decreased glutamate release. The RPE plays an integral role in the transport of retinoids as well as reisomerization of alltrans-retinal to 11-cis-retinal in the visual cycle. Following light exposure, all-trans-retinal is converted into all-trans-retinol by retinal dehydrogenase in the POS before being transported to the RPE by interstitial retinol-binding protein 3 (RBP3). 79, 80 All-trans-retinol can also originate from the blood circulation, being carried by serum retinol-binding protein, before entering the RPE cell basolaterally through the STRA6 (stimulated by retinoic acid 6) protein. 81, 82 Whilst in the RPE, all-trans-retinol is bound to cellular retinol-binding protein and esterified to all-trans-retinyl-ester in the presence of the catalyst lecithin retinol acyl transferase. All-transretinyl-ester undergoes isomerization through RPE65 to produce 11-cis-retinol before being converted by 11-cis-retinol dehydrogenase to produce 11-cis-retinal. 11-cis-retinal is then transported by RBP3 to the POS where it combines with opsin to reform rhodopsin. The cycle is repeated following light exposure whereby the resulting all-transretinal is reconverted to its all-trans-retinol and cycled back to the RPE for reisomerization and oxidation. 8, 81 
IMMUNE PRIVILEGE
The RPE has a central role in maintaining immune privilege in the eye. Firstly, the outer blood-retinal barrier formed by tight junctions between RPE cells creates a microenvironment which allows infiltration into the retina by immune system components to be carefully regulated. Secondly, the RPE itself is capable of secreting immunosuppressive factors, including TGF β, interleukin 11 and interferon β, to downregulate T-cell activity. 83 Thirdly, the presence of Fas ligand on the membrane allows RPE cells to induce apoptosis in Fas expressing effector leukocyte cells. 84, 85 Furthermore, RPE cells which express mass histocompatibility complex (MHC) class I and II are able to act as antigen-presenting cells in the eye. 86, 87 RPE cells can also synthesize or express numerous complement proteins and regulators. PCR analysis of RPE cells revealed that the RPE was capable of local production of complement 3(C3), complement factor B (CFB), complement factor H (CFH), complement factor D (CFD) and complement factor I (CFI). Complementary regulatory proteins membrane cofactor protein (MCP), decay accelerating factor (DAF) and CD59 are also expressed on the RPE membrane. 88 
AGE-RELATED MACULAR DEGENERATION
AMD is an ocular disease associated with aging and characterized symptomatically by impairment of central vision. Classically, AMD is divided into two subtypes: 'early' and 'late' AMD. In the early stages, AMD is marked by increasing and abnormal deposition of extracellular debris between Bruch's membrane and the RPE, known as drusen. Yellowish subretinal lesions known as subretinal drusenoid deposits or pseudodrusen located initially in the outer superior macula are markers for progression of AMD. 89, 90 The progression of early AMD is characterized by large drusen formation and/or clinically visible RPE abnormalities. Late AMD is characterized by the development of geographic atrophy and increasing impairment of central vision. There is currently no treatment for the atrophic form of AMD. Neovascular AMD is the other clinical variant of late AMD and causes more rapid and dramatic loss of central vision and is characterized by choroidal neovascularisation, the development of new blood vessels from the choroid and rarely the retina that often leak into the retina, causing haemorrhage, retinal detachment and eventually disciform scars. Anti-VEGF intravitreal injections are currently the main form of treatment for CNV. Although the pathogenesis of AMD remains unclear, there is evidence that degeneration or dysfunction of RPE cells often occurs in the early AMD pathogenesis and can be a predictor of photoreceptor loss although in cases such as outer retinal atrophy associated with pseudodrusen, photoreceptor loss can precede RPE disease.
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OXIDATIVE STRESS
Oxidative stress has been suggested as a potential integral mechanism of RPE injury in the pathogenesis of AMD. In vitro experiments where RPE cells are exposed to oxidative stress, that is, H 2 O 2 have shown increased apoptosis, decreased proliferation and features of senescence. [96] [97] [98] Apoptotic RPE cells have also been identified in CNV membranes from AMD donor eyes. 99 The underlying mechanism of oxidative stressinduced apoptosis in AMD is thought to be an interference in the protective epidermal growth factor receptor/protein kinase B pathway as well as an activation of apoptosis-promoting factors such as caspase 3 and 9, as triggered by the release of cytochrome c from mitochondria.
97,100 AMD donor eyes have histological evidence of established widespread oxidative damage in patients with advanced GA and also in eyes with CNV to a lesser extent. 101 Genetic evidence of the importance of RPE oxidative stress in the pathogenesis of AMD is supported by transgenic mice having a deletion of the superoxide dismutase 1 (SOD 1) gene. These mice develop clinical features of AMD, including drusen deposition, RPE atrophy and CNV. 102 Carboxyethyl pyrole (CEP) residues, which are oxidized remnants of DHA, have been used as biomarkers in patients with AMD who have increased plasma CEP autoantibodies and accumulation of CEP within the RPE and outer retina. 103 Mice that have been immunized with mouse serum albumin adducted with CEP developed AMD-like lesions similar to GA. 104 Subretinal injections of CEP modified human serum album have also been found to exacerbate angiogenesis in laser-induced CNV mouse models. 105 A major source of oxidative stress in RPE cells is the formation of ROS during phagocytosis of POS. Extracellular H 2 O 2 is presumably generated from the action of NAPH (nicotinamide adenine dinucleotide phosphate) oxidase in a phagosome or from perioxidation of ingested POS lipids. Downregulation of the antioxidant enzyme catalase also occurs during phagocytosis, leading to increased susceptibility of RPE cells to ROS. 29 Lipofuscin, autofluorescent collections of undegradable protein and lipids associated with aging, accumulate in lysosomes of postmitotic cells including RPE cells. Lipofuscin within RPE cells has been postulated to originate from insufficient RPE phagocytosis of POS and it is thought that this may also contribute to the decline in RPE phagocytic function with aging.
106 N-retinyl-N-retinylidene ethanolamine (A2E), a component of lipofuscin, is theoretically susceptible to photo-oxidation from exposure to blue light, generating toxic A2E-epitopes that cause oxidative damage and subsequent caspase 3-mediated apoptosis of RPE cells. 107, 108 However, the role of A2E in the pathogenesis of AMD has recently been questioned. Recent mass spectrometry studies of human RPE have shown that greater amounts of A2E were located in the periphery rather than the central region, incongruent with the spatial distribution of lipid fluorescence. 109, 110 In addition, clinical evaluation of lipofuscin in early AMD patients showed no significant increase compared to agematched controls. 111 Epidemiological studies associating cigarette smoking and sunlight to increased risk of developing AMD support the role of oxidative stress as a key factor in the pathogenesis of AMD. 112 Wang et al. 113 demonstrated exposure to benzo(a)pyrene, the toxic element in cigarette smoke, resulted in apoptosis of cultured RPE cells as well as ultrastructural changes akin to oxidative damage in mice.
The role of oxidative stress in AMD pathogenesis is also supported by the AREDS study which demonstrated high-dose antioxidants (vitamin C, vitamin E and β-carotene) as well as zinc, which increases the activity of enzymes such as SOD and catalase, significantly reduced the progression of intermediate AMD to advanced AMD. 114 The follow-up AREDS2 study in 2013 concluded that the antioxidants lutein and zeaxanthin were effective and safe alternatives to β-carotene which had, as a side-effect, been found to increase lung cancer in smokers. 115 
MITOCHONDRIAL DYSFUNCTION
Impaired mitochondrial function in the RPE appears to be a critical factor in AMD. Mitochondria are an endogenous source of oxidative stress. Mitochondrial injury or dysfunction results in impaired respiration which leads to the increased accumulation of ROS. 116 In a continuous cycle, oxidative stress in mitochondria can exacerbate the generation of ROS, eventually overwhelming RPE cells resulting in apoptosis. Mitochondrial DNA (MtDNA) is a more vulnerable target to oxidative damage than nuclear DNA (nDNA) given its proximity to the ROSproducing inner mitochondrial membrane, relatively poor repair capabilities and its lack of protective histones or other DNA-associated proteins. Furthermore, the coding regions of MtDNA are more predisposed to oxidative damage since there exist a large number of intronless regions with high transcription rates. 100 In vitro experiments, where RPE cells were exposed to oxidative stress demonstrated preferential damage to MtDNA over nDNA along with a decline in mtDNA repair and compromised mitochondrial redox function. 98, 117 In human AMD donor eyes, there is evidence of increased maculaspecific mtDNA damage, mitochondrial heteroplasmic mutations and diminished mtDNA repair capacity in the RPE. 118 The association between AMD and RPE mitochondrial dysfunction was further illustrated in a proteomic analysis of AMD donor eyes demonstrating altered mitochondrial translation factors, decreased ATP synthase subunits and reduced mitochondrial heat shock protein 70 expression (mtHsp70). 119 Important functions of mtHSP70 include regulation of p53-mediated apoptosis, ironsulphur cluster biogenesis, mitochondrial calcium regulation and ATP-dependent transport of nuclearencoded proteins into the mitochondrial matrix. 119 A2E in lipofuscin has been shown to induce apoptosis of RPE cells in a light-dependent manner through a mitochondria-related mechanism. Upon exposure to blue light, A2E binds non-covalently to cytochrome oxidase C (COX), an essential mitochondrial enzyme in oxidative phosphorylation. Upon attachment, A2E exhibits its toxic effect by inhibiting COX causing impaired mitochondrial respiration, generation of ROS and formation of proapoptotic complexes involving cytochrome C. [120] [121] [122] There is also genetic evidence for the association between mitochondrial dysfunction and AMD. In human AMD patients, mtDNA lesions were increased significantly in all regions of the mitochondrial genome compared to age-matched controls where age-related mtDNA lesions only occurred in the common deletion regions. 123 In addition, polymorphisms of ARMS2 gene, which encodes for an outer mitochondrial protein in RPE, is associated with significantly increased predisposition to AMD. 124, 125 Macular dystrophy patients resulting from the A3243G mtDNA mutation display clinical phenotypes similar to AMD including varying levels of RPE atrophy and subretinal deposits. 126, 127 COMPLEMENT DYSREGULATION Inappropriate activation of the complement system has been implicated in AMD pathogenesis. Biochemical analysis of drusen constituents reveals a significant number of complement activators (A2E, amyloid β, immunoglobulins, CRP, advanced glycation end products and cholesterol), complement components and inhibitors. 88 The alternate complement pathway (AP) has been the main complement pathway implicated in AMD pathogenesis. Although there have been reports of classical pathway involvement, with variants of C2 genes and SERPING1 gene encoding c1 inhibitor being associated with AMD, this has not been confirmed in larger case-controlled studies. [128] [129] [130] Genetic variations of the genes encoding AP proteins CFH (inhibitor of AP), [131] [132] [133] CFB 128 , CFI 134, 135 as well as C3 136 component are associated with higher susceptibility to AMD, indicating the significance of AP dysregulation in AMD pathogenesis. Haplotypes of CFH with deletion of CFHrelated proteins protects against AMD. 137 Genetic mutations associated with altered extracellular matrix such as the EFEMP1 and TIMP3 mutations have been associated with inherited macular diseases, displaying local inflammation as well as complement factor deposition. Patients display AMD characteristics such as sub-RPE drusen-like deposits as well as eventual atrophy and CNV. 138, 139 Rodent models with genetic knockout of CFH display structural and functional retina degenerations similar to AMD. Increasing expression of human CFH in this model resulted in the inhibition of AP complement pathway, reduction of sub-RPE deposits as well as prevention of retinal and kidney damage caused by CFH deletion in a dosedependent manner. 140, 141 The process of APmediated RPE cell death which occurs in GA involves lysis of cells marked with C3b by membrane attack complex (MAC) that is modulated by extracellular calcium. 142 The AP also has a critical role in the modulation of CNV in laser-induced models. 143 Complement components C3a, C5a, CFB and MAC induce CNV by upregulating RPE secretion of angiogenic factors including VEGF, TGF-β2 and β-fibroblast growth factor. 144, 145 Consequently, specific inhibition of AP reduced angiogenesis in CNV mouse models. 146 The complement system may have a role in promoting the chronic local inflammatory process in AMD. C3a and C5a are known to have chemotactic properties and can increase RPE expression of the inflammatory cytokines interleukin-1β, interleukin-6, interleukin-8, MCP-1 and granulocytemacrophage colony-stimulating factor (GM-CSF). 147 There is evidence that oxidative stress can render RPE more susceptible to complement-mediated damage.
142,148 RPE cells exposed to oxidative stress exhibited reduced expression of the membrane bound complement inhibitors DAF, CD55 and CD59 and downregulation of CFH. [149] [150] [151] Additionally, mice immunized with CEP display increased deposition of C3d below the RPE. 104 In cultured human RPE cells, complement and oxidative stress synergistically increased VEGF secretion up to 100-fold. 149 
PHOTOBIOMODULATION
Photobiomodulation refers to the non-invasive irradiation of tissue with light in the far-red to nearinfrared light spectrum (630-1000 nm) with delivery methods varying from laser sources to light emitting diode (LED) devices. 152 Photobiomodulation originated in the 1960s shortly after the advent of the laser. Mester et al. 153 were the first to demonstrate the positive effects of photobiomodulation. Using NIR lasers they were able to induce increased hair growth and wound healing in mice and treat non-healing skin ulcers in human patients. Since then the field of photobiomodulation has broadened to include treatment of a range of conditions including wound healing, diabetic ulcers, neurological pain, peripheral nerve injury, stroke and myocardial infarction. 154 More recently, focus has turned to the potential beneficial effects of photobiomodulation as a treatment for blinding retinal diseases. Treatment effects from photobiomodulation has been demonstrated in various retinal disease animal models including light-induced retinal degeneration, 155, 156 AMD, 157 retinitis pigmentosa, 158 diabetic retinopathy 159 and retinopathy of prematurity 160, 161 as evidenced by improved ERG, decreased inflammatory markers and diminished cell loss.
Photobiomodulation has been reported to have positive results in patients with AMD, 162, 163 diabetic retinopathy, 164 amblyopia 165 and retinitis pigmentosa, 166 reflected in improvement of visual acuity and decreased visual field loss. However, these clinical studies range from interventional case series to a single case report. In addition, the mechanism of photobiomodulation particularly on amblyopia is unclear. Hence, the current evidence for the efficacy of photobiomodulation in retinal disease is poor. Nevertheless the mechanism of photobiomodulation and its relative safety should motivate more robust clinical studies.
MECHANISMS OF PHOTOBIOMODULATION
In the far-red and near-infrared light spectrum, COX is the primary photoacceptor. By targeting COX, photobiomodulation modulates electron transfer in the reduction of oxygen during mitochondrial respiration, hence increasing the mitochondrial membrane potential and ATP synthesis (Fig. 2) . Ultimately, this triggers and enhances cellular repair processes and metabolism in photoreceptors, choroid and retinal pigment epithelium. 162 Evidence of COX as the primary target comes from Eels who reported photobiomodulation improved rat retinal function following methanol intoxication which is known to inhibit cytochrome oxidase activity. 167 NIR light treatment of primary cultured neurones reversed the effect of tetrodotoxin by upregulating COX activity. 168 Desmettre et al. 169 found in choroidal layers, that transpupillary application of laser therapy-induced increased expression of heat shock proteins, which are known to stimulate cellular metabolism and prevent premature cell death. Another potential mechanism of photobiomodulation is the unbinding of nitric oxide (NO) from COX as demonstrated by Karu et al. 170 Since NO inhibits mitochondrial respiration, its dissociation from COX would restore mitochondrial oxygen consumption, therefore increasing energy production and boosting cellular metabolic processes. 152 In vitro experiments have reported that photobiomodulation therapy increases phagocytosis and lysosomal activity, cellular processes important in the reduction of inflammation and enhancing repair of the retina. 154 These processes occur from photobiomodulation triggering downstream signalling cascades via ATP, cAMP, NO, ROS and Ca 2+ resulting in eventual gene expression that promotes protein synthesis, anti-inflammatory processes, antioxidants, antiapoptotic proteins as well as cell migration and proliferation. 171 Photobiomodulation usually stimulates mitochondrial ROS production at low levels however it may decrease ROS production during oxidative stress. 172 In addition, photobiomodulation has observed to have a biphasic dose response in vitro in particular relation to ATP levels and mitochondrial potential. 173 
APPLICATIONS IN AMD
The pathogenesis of AMD as discussed above encompasses a complex interplay of oxidative stress, mitochondrial dysfunction and complement dysregulation, likely involving the RPE. Photobiomodulation may prove to be an effective treatment for AMD as there is evidence that it can significantly modulate all of these pathological processes (Table 1. ).
Exposure of NIR light with a dose of 2.88 J/cm 2 to human RPE cells in vitro stimulated a 56% increase in ATP and twofold increase in intracellular NO production at 5 h post-exposure, presumably via unbinding of NO from COX leading to an enhancement in mitochondrial oxidative phosphorylation. 174 Photobiomodulation resulted in a six-fold increase in levels of growth promoting nuclear factor kappa-light-chain-enhancer of activated B cells (NF-KB), an 11-fold increase in levels of apoptosis suppressor protein Bcl-2 and a 70% decrease in levels of the apoptotic effector protein Bax. In RPE cultures exposed to the oxidative stressor H 2 O 2 and challenged with POS, Fumar et al. 175 reported improvement of phagocytosis, increased expression of MerTK and reduced ROS production following treatment with 250 s of 670 mm light at 3.89 mW/cm 2 for four consecutive days. Interestingly, mitochondrial membrane potential was not affected by NIR light in this study. Photobiomodulation has also been demonstrated to protect RPE cells from the lethal effects of thermal laser. 176 There is also considerable evidence of a beneficial effect of photobiomodulation in animal AMD models. In an aged mice model of AMD, Kokkinopoulos 177 for 6 min twice daily for 2 weeks had significantly increased COX, decreased C3 complement deposition in the outer retina as well as reduced inflammatory markers vimentin and glial fibrillary acidic protein (GFAP). There were also notable changes in the morphology of RPE macrophages and dendritic cells however there was no significant change in numbers. The relatively indirect delivery of photobiomodulation through supplemental environmental lighting in this study demonstrated the effectiveness of NIR light in penetrating tissue to reach the target. Calaza et al. 178 reported improved ATP levels in CFH mice following NIR light exposure at 40 mW/cm 2 supporting evidence that photobiomodulation improves oxidative phosphorylation. In a separate experiment, Kokkinopoulos 179 reported 162 where 348 eyes of 203 patients with dry and wet type AMD were exposed to 40 s of transconjunctival 780 nm light from a semiconductor laser diode with 0.3 J/cm 2 delivered to the macula four times over 2 weeks. The treatment group included 146 with cataracts with 182 without. The remaining 20 eyes of 10 patients received sham treatments and served as the control group. There was substantial improvement in both treated groups with 97% of patients with cataracts improving in visual acuity by a mean of two lines and 94.5% of the non-cataract patients by the same amount up to 36 months. The authors also reported reduced pigmentation and cystic drusen as well as improvement in metamorphopsia, dyschromatopsia and relative scotomas. Patients with wet AMD had reduced oedema and bleeding. No change was observed in the control group. The TORPA II study, which examined 42 eyes in 24 patients with dry AMD by Merry et al. 181 consisted of delivering 88 s of 670 nm light at 4-7.7 J/cm 2 through LED-based devices as well as 590 and 790 nm for 35 s delivering 0.1 J/cm 2 in nine treatments over 3 weeks. Following photobiomodulation, there were positive functional changes indicated by improvement of contrast sensitivity and visual acuity at 3 weeks and 3 months as well as anatomical improvement exhibited by decrease in drusen volume and central drusen thickness. However, there are significant flaws in the methodologies of both studies: lack of control arm or significant number discrepancies between treatment groups, large ranges in total dosages delivered in addition to the patient demographic with varying stages of disease. Hence, it is difficult to conclude clinical efficacy of photobiomodulation in these studies. It is noteworthy to mention that in both studies there were no reported adverse effects or subjective discomfort by patients, illuminating an excellent safety profile and suggesting that NIR light treatment is well tolerated. There is also significant variance of power settings and delivery methods of photobiomodulation between in vitro, animal studies and clinical studies. Thus, the optimal treatment parameters of photobiomodulation are poorly defined which poses a problem in its translation to the clinical setting.
CONCLUSION AND FUTURE DIRECTIONS
The RPE is a vital component of the eye and its dysfunction has been implicated in the pathogenesis of AMD. Photobiomodulation is a promising noninvasive therapy that has demonstrated the capacity to ameliorate oxidative stress, mitochondrial dysfunction and complement dysregulation, all of which are key mechanisms of RPE dysfunction leading to AMD.
Although clinical studies of photobiomodulation in AMD patients have reported positive functional and anatomical improvements, these studies suffer from significant flaws in methodology including the lack of a comparative control group. As a result, conclusions regarding clinical efficacy cannot be established. Hence, there is a need for randomized control trials. The LIGHTSITE study which is currently enrolling in Canada, will be a 30-subject, randomized, double-masked, sham-controlled clinical trial examining similar outcomes from the TORPA II study. 181 As previous studies have used varying dosages, duration and frequency of NIR light with varying effectiveness, there is currently no consensus on treatment regimens. Therefore further studies are needed to establish effective treatment parameters.
